Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro

Inflammatory Bowel Diseases

Volumn 18, Issue 3, 2012, Pages 401-408

  Vos, Anne Christine W ^a   Wildenberg, Manon E ^a,b   Arijs, Ingrid ^c   Duijvestein, Marjolijn ^a   Verhaar, Auke P ^a   De Hertogh, Gert ^c   Vermeire, Séverine ^c   Rutgeerts, Paul ^c   Van Den Brink, Gijs R ^a,b   Hommes, Daniel W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

azathioprine; infliximab; regulatory macrophage

Indexed keywords

AZATHIOPRINE; INFLIXIMAB;

ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; ENTERITIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MIXED LYMPHOCYTE REACTION; MONOTHERAPY; PRIORITY JOURNAL; REGULATORY MACROPHAGE; WOUND HEALING;

ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; AZATHIOPRINE; CELL PROLIFERATION; CELLS, CULTURED; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL MUCOSA; LECTINS, C-TYPE; LYMPHOCYTE CULTURE TEST, MIXED; MACROPHAGES; MANNOSE-BINDING LECTINS; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES; WOUND HEALING;

EID: 84857373545     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21818     Document Type: Article

References (22)

1. Targan SR, Hanauer SB, van Deventer SJH, et al. The Crohn's Dc. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor {alpha} for Crohn's disease. N Engl J Med. 1997; 337: 1029-1036.
2. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999; 117: 761-769. (Pubitemid 29468216)
3. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995; 109: 129-135.
4. D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology. 1999; 116: 1029-1034. (Pubitemid 29203012)
5. Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology. 1999; 116: 22-28. (Pubitemid 29013489)
6. D'Haens G, Swijsen C, Noman M, et al. Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. Am J Gastroenterol. 2001; 96: 2564-2568.
7. Feagan BG, Sandborn WJ, Lichtenstein G, et al. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006; 23: 617-628.
8. Vos AC, Wildenberg ME, Duijvestein M, et al. Anti-tumor necrosis factor-alpha antibodies induce regulatory macrophages in an Fc region-dependent manner. Gastroenterology. 2011; 140: 221-230.
9. Hunter MM, Wang A, Parhar KS, et al. In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice. Gastroenterology. 2010; 138: 1395-1405.
10. Verreck FA, de BT, Langenberg DM, et al. Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma- and CD40L-mediated costimulation. J Leukoc Biol. 2006; 79: 285-293. (Pubitemid 44831160)
11. Daley JM, Brancato SK, Thomay AA, et al. The phenotype of murine wound macrophages. J Leukoc Biol. 2010; 87: 59-67.
12. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362: 1383-1395.
13. Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000; 47: 404-409.
14. D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998; 114: 262-267. (Pubitemid 28093532)
15. Arijs I, De HG, Lemaire K, et al. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS One. 2009; 4: e7984.
16. Liang CC, Park AY, Guan JL,. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007; 2: 329-333. (Pubitemid 47040047)
17. Gordon S,. Alternative activation of macrophages. Nat Rev Immunol. 2003; 3: 23-35. (Pubitemid 37328697)
18. Smythies LE, Sellers M, Clements RH, et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest. 2005; 115: 66-75. (Pubitemid 40385506)
19. Kamada N, Hisamatsu T, Okamoto S, et al. Abnormally differentiated subsets of intestinal macrophage play a key role in Th1-dominant chronic colitis through excess production of IL-12 and IL-23 in response to bacteria. J Immunol. 2005; 175: 6900-6908. (Pubitemid 41598935)
20. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1993; 94: 174-181. (Pubitemid 23308385)
21. Reimund JM, Wittersheim C, Dumont S, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol. 1996; 16: 144-150. (Pubitemid 26166392)
22. Zareie M, Singh PK, Irvine EJ, et al. Monocyte/macrophage activation by normal bacteria and bacterial products: implications for altered epithelial function in Crohn's disease. Am J Pathol. 2001; 158: 1101-1109. (Pubitemid 32221802)